Biotheus is a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases.

Biotheus

Biotheus Inc. | 1,314 followers on LinkedIn. To Inspire Each Other and Create Effective Medicines for Humankind | Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Vice President Business Development & Licensing ex-China

Roland Meisel, Ph.D.

Executive Director, GM of Nantong Site

Bingyan He

Healthcare investment in Cowin Venture Capital

Jason (Hai) Jiang

Biotheus - BD Senior Manager

Yanli Du

Biotheus Inc.

We are thrilled to celebrate the grand opening of our biologics (DS/DP) manufacturing facility in Nantong 🎉. At this state-of-the-art facility, we have 3 x 2000L lines dedicated to supporting the global development of our pipeline. #Biologics #Manufacturing

Andy T.

Bispecific antibodies, a novel class of immunotherapies, are showing significant promise in oncology. These engineered antibodies can simultaneously bind to two different antigens, providing unique mechanisms of action. Hematological malignancies are the primary focus of bispecific antibody development. Fast forward to 2022–2023, and we witnessed a dynamic shift, with eight new bispecific approvals, primarily revolutionizing hematological cancer treatments. Nevertheless, numerous bispecific antibodies are under investigation for various solid tumors, including gastric, colorectal, ovarian, prostate, and Lung cancer. Immunocore , Innovent Biologics , Johnson & Johnson Innovative Medicine , Roche , Curonix , Genmab , AbbVie , Merus N.V. , Summit Therapeutics, Inc. , BioNTech SE , Affimed , Biotheus Inc. , Amgen , Regeneron , Qilu Pharmaceuticals , and others showcased their latest research and advancements in bispecific treatments at the American Society of Clinical Oncology (ASCO) 2024. Get an in-depth analysis of bispecific antibodies coverage from the ASCO 2024 conference at https://lnkd.in/gwDBMuqP

DelveInsight Business Research LLP

We have strengthened our partnership with Hansoh Pharmaceuticals on PM1080/HS-20117, a EGFR x cMET bispecific, for development of an ADC product. I would like to thank the team at Hansoh for believing in the potential of PM1080 and excited by their vision in the ADC space. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Biotheus Inc.

Meet our senior team in San Francisco for JPM2024!

BIOT

COM:BIOTHEUS

Biotheus